

START WITH THE **POWER**



SITANUVIA PLUS[®]


(Sitagliptin/ Metformin HCL Tablets)



SITANUVIA PLUS[®]


(Sitagliptin/ Metformin HCL Tablets)

SITANUVIA PLUS TARGETS ALL 3 CORE DEFECTS OF DIABETES



POWERFUL A1C REDUCTIONS VS METFORMIN (1)


powerful glucose reductions beyond metformin alone




Week 24 primary and point results for patients uncontrolled on diet and exercise (intent to treat population)

Starting with **SITANUVIA PLUS** got nearly twice as many patients to goal ⁽¹⁾


Superior efficacy to achieve A1C goal <7% vs metformin alone



Similar rate of GI adverse events vs metformin alone




Significant FPG placebo-adjusted mean reductions ($p < 0.001$)



Week 24 results for patients uncontrolled on diet and exercise (intent to treat population)


Significant 2-hour PPG placebo-adjusted mean reductions ($p < 0.001$)



Week 24 results for patients uncontrolled on diet and exercise (intent to treat population)

Enhancing β -cell function

Effect of Sitagliptin + Metformin on β -Cell Function at 24 Weeks (1)



HOMA- β =homeostasis model assessment for insulin secretion

INDICATIONS AND USAGE

SITANUVIA PLUS

is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

DOSAGE AND ADMINISTRATION

Patients not currently being treated with metformin

Start: Initial combination therapy or maintenance of combination therapy should be individualized and left to discretion of the health care provider. For a patient with type 2 diabetes not currently being treated with metformin, the recommended starting dose is 50 mg sitagliptin/500 mg metformin twice daily, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.

Titrate: The dosage of SITANUVIA PLUS should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin.

Meals: SITANUVIA PLUS should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal side effects due to metformin.

Patients currently being treated with metformin

Start: For a patient currently being treated with metformin, the starting dose of SITANUVIA PLUS should be sitagliptin 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. For patients taking metformin 850 mg twice daily, the recommended starting dose of SITANUVIA PLUS is 50 mg sitagliptin/1000 mg metformin twice daily.

Titrate: The dosage of SITANUVIA PLUS should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin.

Meals: SITANUVIA PLUS should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal side effects due to metformin.

Coadministration with an insulin secretagogue or insulin

Start: Coadministration of SITANUVIA PLUS with an insulin secretagogue (eg, sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.

Titrate: The dosage of SITANUVIA PLUS should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin.

Meals: SITANUVIA PLUS should generally be given twice daily with meals, with gradual dose escalation, to reduce the gastrointestinal side effects due to metformin.

SITANUVIA PLUS®

[Sitagliptin/ Metformin HCL Tablets]



[1] Diabetes Care. 2007;30:1979-1987

**NATIONAL COMPANY FOR
PHARMACEUTICAL INDUSTRY**

الشركة الوطنية للصناعة الدوائية

ALEPPO - SYRIA P.O. 13020
www.ncpipharma.com - Email : info@ncpipharma.com

AlkamaL **L.L.C**
PHARMA & MEDICAL SERVICES الكمال للطبيات والدواء
شركة مسؤولة برأس المال ١٠٠٠٠٠٠٠٠٠ ليرة سورية

Tel.: +963 21 2630051 / 2 / 4
Fax: +963 21 2630053

info@alkamal.com.sy
www.alkamal.com.sy